Treatment of Human B Cell Lymphoma with Monoclonal Anti-Idiotype Antibodies
Human malignant B cell tumours are thought to arise from the proliferation of a single clone of cells (1–4). The immunoglobulin (Ig) that is expressed and in some cases secreted by the tumour cells is limited to the expression of one single VH and VL region, and to a single light chain. The unique variable region of the Ig, the idiotype, may be considered a model tumour marker, since it is found only on the malignant cells. Antibodies directed against this target, anti-idiotype antibodies, would have the potential to destroy malignant tissue while leaving the residual normal lymphoid tissues intact.
KeywordsFatigue Toxicity Leukemia Aspirin Heparin
Unable to display preview. Download preview PDF.
- 6.T. C. Meeker, J. Lowder, D. G. Maloney, R. A. Miller, K. Thielemans, R. Warnke, and R. Levy, A clinical trial of anti-idiotype therapy for B cell malignancy, Blood, 65: 1344 (1985).Google Scholar
- 9.F. R. Macbeth, F. K. Stevenson, G. T. Stevenson, and J.M.A. Whitehouse, Anti-idiotype antibody therapy of patients with non-Hodgkin’s lymphoma. Proceedings of the Second European Conference on Clinical Oncology and Cancer Nursing, Amsterdam, p. 75 (abstr.) (1983).Google Scholar
- 16.R. A. Miller, D. G. Maloney, J. McKillop, and R. Levy, In vivo effects of murine hybridoma monoclonal antibody in a patient with T cell leukaemia, Blood, 58:78 (1981).Google Scholar
- 24.H. Theml, F. Trepel, P. Schick, W. Kaboth, and H. Begemann, Kinetics of lymphocytes in chronic lymphocytic leukemia: Studies using continous H-thymidine infusion in two patients, Blood, 42: 623 (1973).Google Scholar
- 26.T. S. Zimmerman, H. A. Godwin, and S. Perry, Studies of leukocyte kinetics in chronic lymphocytic leukemia, Blood, 31: 277 (1968).Google Scholar
- 27.A. M. Mauer, S. B. Murphy, A. B. Hayes, and G. V. Dahl, Scheduling and recruitment in malignant cell populations, in: “Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells”, B. Drewinko, R. M. Humphrey, eds., Williams and Wilkins, Baltimore (1977).Google Scholar
- 29.H. S. Shin, J. S. Economou, G. R. Pasternack, R. J. Johnson, and M. L. Hayden, Antibody mediated suppression of grafted lymphoma: IV. Influence of time of tumour residency in vivo and tumour size upon the effectiveness of suppression by syngeneic antibody, J. Exp. Med., 144: 1274 (1976).PubMedCrossRefGoogle Scholar
- 34.H. Kubagawa, M. Mayumi, W. D. Gathings, J. F. Kearney, and M. D. Cooper, Extent of clonal involvement in B cell malignancies, in: “Leukaemia Research: Advances in Cell Biology and Treatment”, S. B. Murphy and J. R. Gilbert, eds., Elsevier, Amsterdam p. 65 (1983).Google Scholar